Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study.

@article{Yang2015AssessingEO,
  title={Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study.},
  author={Wan-Lin Yang and Roger D. Kouyos and Alexandra U. Scherrer and J{\"u}rg B{\"o}ni and Cyril A Shah and Sabine Yerly and Thomas Klimkait and Vincent Aubert and C{\'e}dric Hirzel and Manuel Battegay and Matthias Cavassini and Enos Bernasconi and Pietro Vernazza and Leonhard Held and Bruno Ledergerber and Huldrych F. G{\"u}nthard},
  journal={The Journal of antimicrobial chemotherapy},
  year={2015},
  volume={70 12},
  pages={3323-31}
}
BACKGROUND The most recommended NRTI combinations as first-line antiretroviral treatment for HIV-1 infection in resource-rich settings are tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine. Efficacy studies of these combinations also considering pill numbers, dosing frequencies and ethnicities are rare. METHODS We included patients starting first-line combination ART (cART) with or switching from first-line cART without treatment failure to tenofovir… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS